Emerging Issues in HIV Clinical Trials for new ARVs Roundtable

The Maraviroc Experience and the Future

Jayvant Heera
Pfizer Global Clinical Development
New London, Connecticut

September 30, 2010
Washington DC
The Maraviroc Experience and the Future

Objectives

• To illustrate in the context of the maraviroc clinical development program how the landscape of HIV disease has changed

• Considerations on how HIV drug development could evolve to serve the needs of HIV infected patients within this changing landscape
HIV Landscape in 2004

- Large proportion of HIV infected patients were highly treatment experienced (TE) with multi drug resistant virus and needed >3 ARV drugs
  - Patients were viremic with no treatment options
  - Treatment Guidelines → Recommended goal → To decrease Viral Load (VL) in order to delay occurrence of Opportunistic Illnesses
  - VL suppression superseded safety and tolerability
  - Easy to enroll harder to treat patients in clinical studies
  - Treatment Experience was used as a means to enrich the clinical study population with patients harboring drug resistant virus

- Growing proportion started to switch therapy due to tolerability and convenience issues without experiencing virologic failure

- Large Treatment Naïve (TN) Population whose needs were not as urgent as the highly TE

- Maraviroc Clinical Development Program was designed within this 2004 landscape
## Phase 3 Program in Patients with R5 HIV-1 Treatment-Experienced (TE)

<table>
<thead>
<tr>
<th></th>
<th>ARV-naïve</th>
<th>ARV-experienced</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study</strong></td>
<td>1026</td>
<td>1027</td>
</tr>
<tr>
<td><strong>Phase</strong></td>
<td>2b→3</td>
<td>2b/3</td>
</tr>
<tr>
<td><strong>Design</strong></td>
<td>MVC vs. EFV AZT/3TC (CBV)</td>
<td>OBT + PBO or MVC</td>
</tr>
<tr>
<td><strong>Randomization</strong></td>
<td>1:1:1</td>
<td>2:2:1</td>
</tr>
<tr>
<td><strong>Primary Endpoint</strong></td>
<td>%&lt;400/ &lt;50 wk 48</td>
<td>Δ VL at wk 48</td>
</tr>
<tr>
<td><strong>Enrollment</strong></td>
<td>721</td>
<td>601</td>
</tr>
<tr>
<td><strong>Received Maraviroc</strong></td>
<td>360</td>
<td>467</td>
</tr>
</tbody>
</table>

ARV – antiretroviral, EFV - efavirenz (Sustiva), VL - viral load, MVC – maraviroc, PBO - placebo
OBT - optimized background therapy, CBV – Combivir
Phase 3 Program in Patients with R5 HIV-1 Treatment-Naïve (TN)

<table>
<thead>
<tr>
<th></th>
<th>ARV-naïve</th>
<th>ARV-experienced</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study</strong></td>
<td>1026</td>
<td>1027</td>
</tr>
<tr>
<td><strong>Phase</strong></td>
<td>2b→3</td>
<td>2b/3</td>
</tr>
<tr>
<td><strong>Design</strong></td>
<td>MVC vs. EFV AZT/3TC (CBV)</td>
<td>OBT + PBO or MVC</td>
</tr>
<tr>
<td><strong>Randomization</strong></td>
<td>1:1:1</td>
<td>2:2:1</td>
</tr>
<tr>
<td><strong>Primary Endpoint</strong></td>
<td>%&lt;400/ &lt;50 wk 48</td>
<td>Δ VL at wk 48</td>
</tr>
<tr>
<td><strong>Enrollment</strong></td>
<td>721</td>
<td>601</td>
</tr>
<tr>
<td><strong>Received Maraviroc</strong></td>
<td>360</td>
<td>467</td>
</tr>
</tbody>
</table>

**Notes:**
- ARV – antiretroviral, EFV - efavirenz (Sustiva), VL - viral load, MVC – maraviroc, PBO - placebo
- OBT - optimized background therapy, CBV – Combivir
Learnings from the Maraviroc Development Program

• In TE patients
  ‣ Patients in placebo arm discontinued for lack of efficacy relatively early
    - Difficult to obtain meaningful comparative safety data
    - Delay in starting active open label drug may have potentially compromised all possible drugs to use in an OBT

• In TN patients
  ‣ EMA guidance → Patients with low CD4+ T-cell counts included in exploratory studies only if scientific rationale and if data are available from patients with higher CD4+ T-cell counts
    - CD4+ entry criteria can then be relaxed in phase 3 studies
  ‣ Studies in developing nations presents several challenges. Social and cultural issues need to be addressed for successful clinical study conduct
  ‣ In Non-inferiority studies, still need to demonstrate a significant advantage over existing therapy

• Complexities of developing a drug-diagnostic assay pair
Maraviroc Regulatory Approval in TE patients

Includes all patients who received at least one dose of study medication

- Greater response on maraviroc vs placebo maintained regardless of
  - Baseline CD4 count
  - Screening HIV RNA
- Durability maintained through 96 weeks of therapy
- Approvals in US and EU → Aug-Sep ‘07
  Traditional approval → Nov ‘08

HIV-1 RNA value imputed as baseline if missing or if patient discontinued before 48 weeks

\[ p<0.0001 \text{ vs placebo + OBT} \]

Hardy D, et al. 15th CROI 2008; Poster 792, Hardy D et al. 9th ICDTHI 2008; Poster O425
Maraviroc Regulatory Approval in TN patients

- Treatment differences fell within the Non-Inferiority Margin in the ESTA Population at Week 48
- US and Canada approvals → Nov ’09, Apr 2010
- EU considered application not approvable
- Is demonstration of a positive risk benefit profile sufficient to offer prescribers alternative options or is an improvement over an existing risk benefit profile essential?

*Difference (adjusted for randomization strata); †Lower bound of 1-sided 97.5% confidence interval
Includes patients who received at least one dose of study medication; missing values classified as failures
Key Post Marketing Commitments for Maraviroc

First host targeted HIV therapeutic and First in class

- 5 year long term follow-up of registrational studies (A4001026, 1027 and 1028)
- A4001067: 3000 patient safety registry (POEM)
  - Non-randomized, controlled, observational study to provide additional safety data on incidence of mortality, liver failure, malignancy, myocardial ischemia or infarction, rhabdomyolysis, and Category C infections
- A4001098: HCV and/or HBV co-infected patients
- A4001031: Pediatric study in 2 to 18 years of age
- Deferred pediatric study under PREA from birth to ≤ 2 years of age
- Development of a tropism diagnostic test
  - Submit application for a diagnostic test to FDA, on the part of a diagnostic sponsor(s) or as sponsor. Test to demonstrate performance adequate to identify an appropriate patient population for maraviroc use
HIV Landscape in 2013 and beyond

- Approximately 80% of patients across US and EU have undetectable VLs → very few patients available to recruit into TE studies
- Increasing life expectancy → Increasing duration on ARVs
- There will be multiple NRTI Fixed Dose Combinations (FDCs): Each patient may only benefit from one FDC
- There are multiple QD options
- There will be generic efavirenz
- Same safety and efficacy required from regimens regardless of Treatment experience
Morbidity and mortality causes in the virologically controlled patient and their relationship to inflammation

- Patients who have achieved long-term viral load control on HAART are now increasingly experiencing premature onset of diseases associated with aging, such as:
  - cardiovascular (CV) disease
  - non-AIDS cancers
  - liver disease
  - renal disease
- These serious non-AIDS diseases are being observed at an excess rate compared to the general population.
- These endpoints were initially not thought to be related to immune deficiency or HIV, however recent data suggests that persistent HIV-induced immune dysfunction is associated with this excess.
- ARVs may also contribute to many of these endpoints.
- Although there’s a switch in paradigm to treating patients earlier, many patients do present with very advanced disease.
  - These patients are more likely to experience these clinical endpoints.

Needs of an HIV patient in 2013 and beyond

- Cure (elusive)

- Need for therapies that minimize residual inflammation and immune activation
  - To decrease non-HIV associated events

- Non-NRTI containing Fixed Dose Combinations

- Regimens that are safe and effective over the long term, convenient and well tolerated in ALL patients regardless of treatment experience
  - Trials should demonstrate this in patients whose virus is sensitive to all drugs in the regimen being tested regardless of treatment experience

- There are still patients with multi drug resistant virus in need of new therapies with novel mechanisms of action
  - We would predict that over time this need will not diminish as multi drug resistance is likely to increase as with most infectious diseases
Registrational Clinical Study Design Issues

- In TE studies that enroll patients with multi drug resistant virus, having a fully active background is necessary to achieve current goals of therapy
  - Potent activity of backbone decreases the ability to ascertain contribution of the investigational agent
    - DRV/r + RAL + [ETR or LRV]

- Resistance criteria in non-inferiority studies need to account for both test drug and comparator, further limiting patient pool, e.g.:
  - ETR – less activity against Y181C
  - LRV *in vitro* – active against Y181C
  
  Issue: Must exclude Y181C if ETR is used as a comparator
  Precludes ability to fully demonstrate LRV activity

- Are large scale pivotal studies in highly TE patients with multi drug resistant virus still feasible?
Three Proposed studies for a drug with a new Mechanism of Action

1. **Pivotal: Virus is sensitive to all drugs (regardless of TE)**
   - OBT + Test Drug or SOC1
   - Eg. 2 sensitive NRTIs + Test Drug or EFV

2. **Pivotal: Virus is sensitive to all drugs (regardless of TE)**
   - OBT + Test Drug or SOC2
   - Eg. Boosted PIs + Test Drug or 2NRTI

3. **Supportive: Patients with Multi Drug Resistant Virus**
   - Open Label study to gather additional safety and PK information

- All studies would collect SMART endpoints, store samples for biomarkers and use scores combining organ functions (Justice)
Implications of the Evolving HIV Landscape for Drug Development

• Should labeling eliminate reference to Treatment Naïve vs Experienced populations?
  ‣ Would sensitivity of virus to the drug and/or drug combination be more appropriate for including patients in studies and characterizing the drug in a label?

• Do we need to include a method of collecting endpoints (SMART type) that can be adjudicated?

• In addition to biomarkers, should scores combining different organ functions be included for the purpose of comparative effectiveness?

• Post approval commitments
  ‣ FDA –Prospective Observational Studies Safety Registry
  ‣ Should long term safety of drugs and drug combinations be more appropriately assessed independently and driven by large cohorts supported by multiple pharmaceutical companies in a model similar to the HAART oversight committee rather than by individual companies?
  ‣ Allows for larger databases to explore rare events, improves signal detection
    ‣ Slow uptake of new drug
    ‣ Inherent bias of cohort studies, but these also apply to safety registry